Anne C. Deitz

3.2k total citations
27 papers, 1.5k citations indexed

About

Anne C. Deitz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Anne C. Deitz has authored 27 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in Anne C. Deitz's work include Lung Cancer Treatments and Mutations (9 papers), Carcinogens and Genotoxicity Assessment (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Anne C. Deitz is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Carcinogens and Genotoxicity Assessment (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Anne C. Deitz collaborates with scholars based in United States, Spain and Japan. Anne C. Deitz's co-authors include David W. Hein, Mark A. Doll, Timothy R. Rebbeck, Wei Zheng, Timothy D. Rustan, Fred F. Kadlubar, Graham A. Colditz, Rulla M. Tamimi, Mark Galan and Laura C. Collins and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Analytical Biochemistry.

In The Last Decade

Anne C. Deitz

26 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anne C. Deitz United States	15	727	503	498	416	163	27	1.5k
Cathryn H. Bock United States	23	430 0.6×	590 1.2×	392 0.8×	794 1.9×	245 1.5×	57	1.7k
Nan Soon Wong Singapore	20	686 0.9×	241 0.5×	321 0.6×	192 0.5×	217 1.3×	39	1.1k
Hyun Jo Youn South Korea	25	674 0.9×	634 1.3×	503 1.0×	208 0.5×	185 1.1×	116	1.9k
Angela S. Wenzlaff United States	23	437 0.6×	464 0.9×	193 0.4×	534 1.3×	237 1.5×	44	1.3k
Araba A. Adjei United States	19	377 0.5×	616 1.2×	145 0.3×	214 0.5×	335 2.1×	32	1.3k
Wen Xia China	23	477 0.7×	434 0.9×	229 0.5×	196 0.5×	59 0.4×	88	1.2k
Silke Kropp Germany	26	711 1.0×	607 1.2×	427 0.9×	236 0.6×	375 2.3×	33	1.9k
Maarten J. Deenen Netherlands	22	918 1.3×	462 0.9×	134 0.3×	224 0.5×	88 0.5×	67	1.4k
Craig Eagle United States	13	536 0.7×	254 0.5×	299 0.6×	239 0.6×	216 1.3×	26	1.6k
Hirdesh Uppal United States	19	1.0k 1.4×	572 1.1×	373 0.7×	321 0.8×	316 1.9×	33	2.0k

Countries citing papers authored by Anne C. Deitz

Since Specialization

Citations

This map shows the geographic impact of Anne C. Deitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne C. Deitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne C. Deitz more than expected).

Fields of papers citing papers by Anne C. Deitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne C. Deitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne C. Deitz. The network helps show where Anne C. Deitz may publish in the future.

Co-authorship network of co-authors of Anne C. Deitz

This figure shows the co-authorship network connecting the top 25 collaborators of Anne C. Deitz. A scholar is included among the top collaborators of Anne C. Deitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne C. Deitz. Anne C. Deitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kuang, Yuting, Anne C. Deitz, M. Catherine Pietanza, et al.. (2022). Incidence of Pneumonitis Among Limited Stage Small Cell Lung Cancer Patients Exposed to Concurrent Chemoradiation: A Systematic Literature Review and Meta-Analysis. Clinical Lung Cancer. 23(8). 659–669.

Kuang, Yuting, Christine M. Pierce, Hsiu‐Ching Chang, et al.. (2022). Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis. Lung Cancer. 174. 174–185. 15 indexed citations

Pierce, Christine M., Yuting Kuang, Anne C. Deitz, et al.. (2021). Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A meta-analysis.. Journal of Clinical Oncology. 39(15_suppl). e20532–e20532. 1 indexed citations

Bonomi, P., Meredith K. Chuk, Alexander I. Spira, et al.. (2020). Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer. Therapeutic Innovation & Regulatory Science. 54(5). 1208–1214. 2 indexed citations

Barlési, Fabrice, Edward B. Garon, Dong‐Wan Kim, et al.. (2019). Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC. Journal of Thoracic Oncology. 14(5). 793–801. 48 indexed citations

Dietel, Manfred, Н. А. Савелов, Patrick Micke, et al.. (2019). Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study. Lung Cancer. 134. 174–179. 102 indexed citations

Dietel, Manfred, Н. А. Савелов, Patrick Micke, et al.. (2018). 130O Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): The global, multicentre EXPRESS study. Journal of Thoracic Oncology. 13(4). S74–S75. 13 indexed citations

Brahmer, Julie R., Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2017). PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024. Journal of Thoracic Oncology. 12(1). S8–S9. 10 indexed citations

Brahmer, Julie R., Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2017). Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. The Lancet Oncology. 18(12). 1600–1609. 255 indexed citations

10.

Barlési, Fabrice, Edward B. Garon, Dongwook Kim, et al.. (2016). Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC. Annals of Oncology. 27. vi422–vi422. 9 indexed citations

11.

Tamimi, Rulla M., Heather J. Baer, Jonathan D. Marotti, et al.. (2008). Comparison of molecular phenotypes of ductal carcinoma in situand invasive breast cancer. Breast Cancer Research. 10(4). R67–R67. 272 indexed citations

12.

Deitz, Anne C., Nathanial Rothman, Timothy R. Rebbeck, et al.. (2004). Impact of Misclassification in Genotype-Exposure Interaction Studies: Example of N-Acetyltransferase 2 (NAT2), Smoking, and Bladder Cancer. Cancer Epidemiology Biomarkers & Prevention. 13(9). 1543–1546. 46 indexed citations

13.

Ning, Baitang, et al.. (2003). Increased transcriptional activity of the CYP3A4*1B promoter variant. Environmental and Molecular Mutagenesis. 42(4). 299–305. 147 indexed citations

14.

Zheng, Wei, Anne C. Deitz, Deborah R. Campbell, et al.. (1999). N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk.. PubMed. 8(3). 233–9. 93 indexed citations

15.

Hein, David W., Ronald J. Ferguson, Mark A. Doll, & Anne C. Deitz. (1997). Recombinant expression and catalytic analysis of rapid and slow acetylator Syrian hamster chimeric NAT2 alleles. Archives of Toxicology. 71(5). 306–313. 1 indexed citations

16.

Doll, Mark A., Wen G. Jiang, Anne C. Deitz, Timothy D. Rustan, & David W. Hein. (1997). Identification of a Novel Allele at the HumanNAT1Acetyltransferase Locus. Biochemical and Biophysical Research Communications. 233(3). 584–591. 53 indexed citations

17.

Deitz, Anne C., Mark A. Doll, & David W. Hein. (1997). A Restriction Fragment Length Polymorphism Assay That Differentiates HumanN-Acetyltransferase-1 (NAT1) Alleles. Analytical Biochemistry. 253(2). 219–224. 47 indexed citations

18.

Hein, David W., Mark A. Doll, Adrian J. Fretland, et al.. (1997). Rodent models of the human acetylation polymorphism: Comparisons of recombinant acetyltransferases. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 376(1-2). 101–106. 61 indexed citations

19.

Feng, Yi, Wen G. Jiang, Anne C. Deitz, & David W. Hein. (1996). 3,2′-Dimethyl-4-aminobiphenyl-DNA Adduct Formation in Tumor Target and Nontarget Organs of Rapid and Slow Acetylator Syrian Hamsters Congenic at theNAT2Locus. Toxicology and Applied Pharmacology. 140(2). 315–321. 11 indexed citations

20.

Doll, Mark A., Adrian J. Fretland, Anne C. Deitz, & David W. Hein. (1995). Determination of HumanNAT2Acetylator Genotype by Restriction Fragment-Length Polymorphism and Allele-Specific Amplification. Analytical Biochemistry. 231(2). 413–420. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact